Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).

导出原文传递

翻译打印收藏纠错

第一作者： Shota,Fukuoka

第一单位： Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.;Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan.

作者： Shota,Fukuoka ^[1] ; Hiroki,Hara ^[2] ; Naoki,Takahashi ^[2] ; Takashi,Kojima ^[3] ; Akihito,Kawazoe ^[3] ; Masako,Asayama ^[2] ; Takako,Yoshii ^[2] ; Daisuke,Kotani ^[3] ; Hitomi,Tamura ^[4] ; Yuichi,Mikamoto ^[4] ; Nami,Hirano ^[4] ; Masashi,Wakabayashi ^[4] ; Shogo,Nomura ^[4] ; Akihiro,Sato ^[4] ; Takeshi,Kuwata ^[5] ; Yosuke,Togashi ^[6] ; Hiroyoshi,Nishikawa ^[6] ; Kohei,Shitara ^[3]

作者单位： Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.;Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan. ^[1] Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan. ^[2] Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. ^[3] Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan. ^[4] Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan. ^[5] Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan. ^[6]